Provided by Tiger Trade Technology Pte. Ltd.

Kazia Therapeutics Limited

13.41
-0.2650-1.94%
Post-market: 13.410.00000.00%19:30 EDT
Volume:148.99K
Turnover:1.99M
Market Cap:153.18M
PE:-1.97
High:13.96
Open:13.67
Low:13.06
Close:13.67
52wk High:17.40
52wk Low:4.86
Shares:11.43M
Float Shares:8.68M
Volume Ratio:1.13
T/O Rate:1.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.8190
EPS(LYR):-12.3849
ROE:-106.90%
ROA:-25.70%
PB:4.60
PE(LYR):-1.08

Loading ...

Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer

THOMSON REUTERS
·
Jul 28

Kazia Therapeutics Ltd : Btig Initiates Coverage with Buy Rating; Price Target $34

THOMSON REUTERS
·
Jul 01

Kazia Therapeutics CFO James Levine files initial beneficial ownership statement

Reuters
·
Jun 16

ADRs Advance; 111 Inc. Climbs 14%

Dow Jones
·
Jun 13

Kazia Therapeutics Initiated at Buy by Lake Street

Dow Jones
·
Jun 11

Kazia Therapeutics initiated with a Buy at Lake Street

TIPRANKS
·
Jun 11

Kazia Therapeutics director Ebru Davidson files initial beneficial ownership statement

Reuters
·
Jun 04

Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN) and Kazia Therapeutics (KZIA)

TIPRANKS
·
Jun 03

Kazia Therapeutics Names James Levine CFO

MT Newswires Live
·
Jun 02

Kazia Therapeutics names James Levine CFO effective June 1

Reuters
·
Jun 02

Kazia Therapeutics Appoints James Levine as Chief Financial Officer

THOMSON REUTERS
·
Jun 02

Kazia expands Phase 1b paxalisib trial in advanced triple-negative breast cancer to 36 patients

Reuters
·
May 26

Kazia Therapeutics Expands Ongoing Phase 1B Trial of Paxalisib in Advanced Breast Cancer

THOMSON REUTERS
·
May 26

Kazia Therapeutics Ltd - Planned Enrollment in Phase 1B Trial to Increase From 12 to 36 Patients

THOMSON REUTERS
·
May 26

Kazia Therapeutics files beneficial ownership statement for Chief Scientific Officer Sudha Rao

Reuters
·
May 20

Kazia Therapeutics publishes corporate overview outlining oncology pipeline and development plans

Reuters
·
Apr 28

Kazia Therapeutics appoints Sudha Rao as Chief Scientific Officer

TIPRANKS
·
Apr 15

Press Release: Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform

Dow Jones
·
Apr 15

BRIEF-Kazia Therapeutics Ltd - Buys Global Rights To Setdb1 Platform With $1.39 Million Upfront Payment

Reuters
·
Apr 14

Kazia Therapeutics Ltd - Buys Global Rights to Setdb1 Platform With $1.39 Mln Upfront Payment

THOMSON REUTERS
·
Apr 14